Tools, such as MammaPrint and Oncotype DX, aid in the decision if systemic therapy could be omitted or not [114, 115], but are also mainly focused on ER-positive patients and early-stage breast cancer [116], and they might not be accessible for every patient [117–119]. This evidence concerns the gene ESR1 and breast cancer.